There was also the proposed merger between Coeptis & CURE

New Post Public Reply Private Reply Replies (0) Message Board
Mauibound freegriff #29634
666
There was also the proposed merger between Coeptis & CURE Pharma in Nov. 2019
https://curepharmaceutical.com/press-releases...ertension/

CURE Pharmaceutical
CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today...

Important to note one of CURE's delivery system allows drugs to cross the BBB via an Oral flim....which drug does AMBS have that also crosses the BBB?
Eltoprazine does .oh, CBD also crosses the BBB
(don't forget AMBS' deal with Hempori)
https://www.globenewswire.com/news-release/20...mpori.html

I found that really interesting because
Lauren Chung, PhD is on the BOD of TODOS and was (no longer) on the board of CURE.

(That's why I believethe deal with EMOR was important. EMOR had a deal with another company PetVivo which has a film tech they were working on)

Also to note she is a
Former Partner at Yozuma
https://www.bloomberg.com/profile/person/20053925

And former BOD member on Aditxt (think TolloTest now)
https://www.businesswire.com/news/home/202106...-Directors

I think she will play a critical role in some way with Elto Pharma, Coeptis & CURE.

Other names associated and to look out for is
Modi Obochi -
With Todos moving towards a Nasdaq listing, much of our attention has focused on our subsidiary Elto Pharma’s transaction with Coeptis Pharmaceuticals, which recently hired Modi Obochi, MD MBA as Chief Executive Officer.
https://www.globenewswire.com/news-release/20...lders.html

Mike Rea - still with the 5 year deal from 2019
He was the one aligning the deal between AMBS & Coeptis at the time.
https://www.biospace.com/article/releases/ama...sidiaries/

Remeber Hempori's CBD pain cream was gaining traction a while back. Hempri is still selling products
https://www.hempori.com

I believe they will be testing Eltoprazine & CBD in combination therapy via Cure's CUREform™ Portfolio
https://curepharmaceutical.com/pharmaceutical...-delivery/
(Oral film, cream, chewable and eye drops.)

None of it was "truly" dead. (IMO) just couldn't raise any more cash and had to regroup which AMBS is doing along with Elto Pharma.

Again, very interesting to see what comes of all of this.
No coincidence things are beginning to move again with Todos quickly gaining traction and increased revenues.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

How Neo Pepe Coin is Capturing Investor Attention with Presale Growth

Updated Category News Views 165

Neo Pepe Coin: Breaking Ground in the Cryptocurrency World Neo Pepe Coin ($NEOP), an emergent player in the cryptocurrency landscape, has been making waves as it progresses through multiple presale stages. This new digital currency is not only attracting crypto enthusiasts but also garnering interest from larger investors or 'whales' looking for promising opportunities. A...

Continue Reading
Upcoming Conference Call for Bio-Techne's Q1 2025 Insights

Updated Category News Views 70

Upcoming Conference Call for Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) has recently announced an upcoming conference call dedicated to discussing its financial results for the first quarter of fiscal year 2025. This important event is set for a morning slot to ensure that all stakeholders can participate and gain insights into the company's performance. Details of...

Continue Reading
Modella AI's PathChat DX Receives Major FDA Recognition

Updated Category News Views 373

Modella AI's PathChat DX Achieves Breakthrough Device Designation BOSTON -- Modella AI, a pioneer in generative and agentic artificial intelligence for biomedicine, is excited to announce that its advanced generative AI co-pilot, PathChat DX, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This remarkable recognition...

Continue Reading
Nicholas Wealth Unveils New Distribution Rate for FIAX ETF

Updated Category News Views 116

Nicholas Wealth Announces New Distribution Rate for FIAX ETF Nicholas Wealth, a well-respected player in the actively managed income exchange-traded funds (ETFs) space, has revealed an exciting increase in the distribution rate for the Nicholas Fixed Income Alternative ETF (FIAX) to 8.04%. This significant change underscores their dedication to delivering strong returns...

Continue Reading
Understanding Voting Rights and Capital in Investments

Updated Category News Views 191

Understanding Total Voting Rights in Investment Firms Investors often seek clarity regarding their holdings, and a key aspect of this is understanding total voting rights and share capital. Recently, significant information was disclosed by Hargreave Hale AIM VCT PLC, and it’s worth exploring what this means. Company Overview Hargreave Hale AIM VCT PLC stands out in the...

Continue Reading